Document is current
Any future updates will be listed below
-
Authors
,
Verzoni, Elena
Cartenì, Giacomo
Cortesi, Enrico
Giannarelli, Diana
De Giglio, Andrea
Sabbatini, Roberto
Buti, Sebastiano
Rossetti, Sabrina
Cognetti, Francesco
Rastelli, Francesca
Sobrero, Alberto
Turci, Daniele
Sternberg, Cora N.
Porta, Camillo
Cappuzzo, Federico
Tortora, Giampaolo
Tassinari, Davide
Panni, Stefano
Pazzola, Antonio
Surico, Gianmarco
Raimondi, Alessandra
De Giorgi, Ugo
Procopio, Giuseppe
-
Funding
Funding for this research was provided by:
Bristol-Myers Squibb (not applicable)
- License Information
-
More Information
Article History
Received: 14 November 2018
Accepted: 26 March 2019
First Online: 3 April 2019
Ethics approval and consent to participate
: The Early Access Program for nivolumab received the approval by the Ethics Committee of each Italian Center included in the program.
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
